Metastatic Breast Cancer
Conference Coverage
How AI is, or will soon be, relevant in radiation oncology
Radiation oncologists at ASTRO 2022 discuss practical applications of AI, and new research findings.
From the Journals
Chronic stress, especially race related, may hasten cancer death
High allostatic load was associated with an 80% increased risk of cancer death among all study participants.
From the Journals
Third COVID booster benefits cancer patients
For the first time, researchers have quantified the benefits of boosters for COVID-19 in cancer patients.
Conference Coverage
Findings may be practice changing for early breast cancer patients
A radiation boost to the tumor bed during whole breast irradiation was as safe and effective as delivering the boost sequentially.
From the Journals
Study affirms better breast cancer outcomes when chemo comes first
Survival is better when high-risk breast cancer patients receive chemo first, followed by abemaciclib and estrogen therapy.
Diminutio
Cancer as a full contact sport
The complexity of cancer care has long necessitated a team approach to planning cancer treatment.
From the Journals
Cost paramount when choosing metastatic breast cancer treatment
“Our analysis provides quantifiable evidence to help providers choose lower priced, but equally effective sequences of drugs.”
News
FDA OKs selpercatinib for adults with RET-fusion+ solid tumors
In 2020, selpercatinib received accelerated approval for lung and thyroid RET-positive tumors.
Conference Coverage
High BMI linked to better survival for cancer patients treated with ICI, but for men only
The reasons behind the findings and implications for treatment are unknown, as is whether it applies to patients with specific cancers.
Conference Coverage
A farewell to arms? Drug approvals based on single-arm trials can be flawed
Objective responses, not time-dependent survival outcomes, should be endpoints for single-arm trials, with results only used for conditional...
Conference Coverage
Time to cancer diagnoses in U.S. averages 5 months
Diagnosis time varied significantly across tumor types, as well as within the same tumor type.